Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS20045027HPVENSG00000149295.14protein_codingDRD2NoNo1813P14416
TVIS20049925HPVENSG00000149295.14protein_codingDRD2NoNo1813P14416
TVIS20025509HPVENSG00000149295.14protein_codingDRD2NoNo1813P14416
TVIS20049443HPVENSG00000149295.14protein_codingDRD2NoNo1813P14416
TVIS44014966HTLV-1ENSG00000149295.14protein_codingDRD2NoNo1813P14416
TCGA Plot Options
Drug Information
GeneDRD2
DrugBank IDDB06144
Drug NameSertindole
Target IDBE0000756
UniProt IDP14416
Regulation Typeantagonist
PubMed IDs16925508; 11752352; 19506838; 18293356; 20856607
CitationsLindstrom E, Levander S: Sertindole: efficacy and safety in schizophrenia. Expert Opin Pharmacother. 2006 Sep;7(13):1825-34.@@Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.@@Mork A, Witten LM, Arnt J: Effect of sertindole on extracellular dopamine, acetylcholine, and glutamate in the medial prefrontal cortex of conscious rats: a comparison with risperidone and exploration of mechanisms involved. Psychopharmacology (Berl). 2009 Sep;206(1):39-49. doi: 10.1007/s00213-009-1578-4. Epub 2009 Jun 9.@@Seeman P: Dopamine D2(High) receptors moderately elevated by sertindole. Synapse. 2008 May;62(5):389-93. doi: 10.1002/syn.20498.@@Cincotta SL, Rodefer JS: Emerging role of sertindole in the management of schizophrenia. Neuropsychiatr Dis Treat. 2010 Sep 7;6:429-41.
GroupsApproved; Investigational; Withdrawn
Direct ClassificationPhenylpyrroles
SMILESFC1=CC=C(C=C1)N1C=C(C2CCN(CCN3CCNC3=O)CC2)C2=C1C=CC(Cl)=C2
Pathways
PharmGKBPA164784002
ChEMBLCHEMBL12713